The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

Five years ago, Viking Therapeutics (NASDAQ: VKTX) was an unknown, clinical-stage biotech. It hardly stood out in a sea of ...

Three Fool.com contributors have identified what they believe are no-brainer growth stocks to buy in October. Here's why they ...

The future of the weight loss market might not revolve around GLP-1 drugs.

In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company ...

The market's enthusiasm is also related to Eli Lilly's revenue soaring 36% year over year to $11.3 billion, fueled by the success of numerous portfolio stars including GLP-1 drugs Mounjaro and ...

New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.

In a report released on October 10, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Anders Carlson, Matt Orzech welcome challenges from Greg Joseph, Peter Bowden ...

Leaders worried the former president could force Ukraine to cede land to Russia in exchange for a ceasefire if he wins the election ...